An Official Website of the United States Government
Company Information:
Name:
PULMOKINE, INC.
Address:
68 QUEEN ANNE DR
SLINGERLANDS, NY 12159-9385
SLINGERLANDS, NY 12159-9385
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
A novel JAK inhibitor for the treatment of pulmonary arterial hypertension
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Lawrence S. Zisman
Award Amount:
$311,629.00
Abstract:
DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a rare disease associated with high morbidity and mortality. The purpose of this proposal is to develop a novel combined JAK1/JAK2 inhibitor or more selective JAK2 inhibitor for
PAH that will be delivered by inhalation.… More
A PDGFR inhibitor for the treatment of pulmonary arterial hypertension
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Lawrence S. Zisman
Award Amount:
$351,008.00
Abstract:
DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a devastating disease associated with high morbidity and mortality. The purpose of this proposal is to develop a novel highly selective platelet derived growth factor receptor (P
DGFR) inhibitor for PAH that will be… More
An inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hyper
Award Year / Program / Phase:
2012 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Lawrence S. Zisman – 518-573-8315
Award Amount:
$2,267,504.00
Abstract:
DESCRIPTION (provided by applicant): The purpose of this Phase II project is to develop a new treatment for pulmonary arterial hypertension (PAH) consisting of the inhaled platelet derived growth factor receptor (PDGFR) inhibitor PK10453. PAH is a diseaseof the pulmonary vasculature associated with… More